Outcomes With The Use Of Hydrus Microstent Implant For Trabecular Bypass: Experience From A District General Hospital In The United Kingdom
Published 2023 - 41st Congress of the ESCRS
Reference: PO0842 | Type: Free paper | DOI: 10.82333/tpgz-e855
Authors: Aprajita Sinha* 1 , Ojas Sharma 2 , Tarun Sharma 1
1Ophthalmology,Worcestershire Acute Hospitals NHS Trust,Worcester,United Kingdom, 2Public Health,Worcestershire Acute Hospitals NHS Trust,Worcester,United Kingdom
Purpose
To assess the safety and efficacy of trabecular bypass stent surgery with Hydrus stent in cases with uncontrolled POAG either in combination with phacoemulsification or as standalone procedure.
Setting
Cataract and glaucoma remain major causes of blindness all over the world. Combined glaucoma and cataract surgery are now becoming popular with the advent of minimally invasive glaucoma surgery devices. Hydrus Microstent has demonstrated significant reduction in intraocular pressure and medication use in primary open-angle glaucoma (POAG) patients.
Methods
We included 30 consecutive cases of POAG with 12-month postoperative data. 30 eyes of 29 patients completed 12 month follow up after this surgery. We studied the percentage drop in intraocular pressure (IOP), reduction in mean number of eye drops and prevention of 2nd stage trabeculectomy surgery and associated complications.
Results
There was a 20% drop in IOP achieved in 25 eyes (83.33%) while 21 eyes (70%) achieved >30% IOP drop. 6 eyes (20%) required 2ndstage filtration surgery within 12 months. The mean number of medications was reduced from 4.24 preoperatively to 3.23 postoperatively. No complications were reported.
Conclusions
Hydrus Microstent either as a standalone procedure or combined with phacoemulsification is an efficient and safe modality of treatment for patients with medically uncontrolled moderate to advanced primary open-angle glaucoma.